Changing strategies for hepatitis C testing

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1391-1395

  Teo, Chong Gee ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 333; ABT 450; ACH 1625; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; GS 9256; GS 9451; IDX 184; INTERFERON; LOMIBUVIR; MERICITABINE; MK 5172; NARLAPREVIR; PSI 938; RIBAVIRIN; RITONAVIR; SCY 465; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR;

ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIVIRAL THERAPY; BLOOD SAMPLING; CHRONIC PATIENT; ERADICATION THERAPY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH CARE PRACTICE; HEPATITIS C; HEPATITIS C RAPID TEST; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; INFECTION CONTROL; INFECTION PREVENTION; NUCLEIC ACID TEST; ORAQUICK HCV RAPID ANTIBODY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; VIREMIA; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT-OF-CARE SYSTEMS; RNA, VIRAL; UNITED STATES; VIREMIA;

EID: 84871941755     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2468     Document Type: Review

References (26)

1. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New directacting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61 Suppl 1:i36-i46.
2. HHS. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis. Washington, DC: US Department of Health and Human Services 2011; pp. 1-76.
3. Centers for Disease Control and Prevention. Viral Hepatitis Resource Center. (Updated 20 March 2012. Accessed 16 October 2012.) Available from http://www.cdc.gov/hepatitis/Resources/MtgsConf/HCVSymposium2011.htm
4. Alter MJ, Kuhnert WL, Finelli L, Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52 RR-3:1-13.
5. Vermeersch P, Van Ranst M, Lagrou K. Validation of a strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory. J Clin Virol 2008; 42:394-398.
6. Department of Health and Ageing. Third National Hepatitis C Strategy 2010-2013. (Updated 31 July 2010. Accessed 16 October 2012.) Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/ ohp-nationalstrategies-2010-hcv/$File/hcv.pdf
7. Smith BD, Jewett A, Drobeniuc J, Kamili S. Rapid diagnostic HCV antibody assays. Antivir Ther 2012; 17:1409-1413.
8. Ward JW. Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals. Antivir Ther 2012; 17:1397-1401.
9. Pesano RL. Testing and reporting practices for improved management of hepatitis C. Antivir Ther 2012; 17:1403-1407.
10. Association of Public Health Laboratories. Viral Hepatitis Testing. 2009 APHL Survey Report. May 2010. (Updated 30 May 2009. Accessed 16 October 2012.) Available from http://www.aphl.org/AboutAPHL/publications/Documents/ID-2010May- 2009-Viral-Hepatitis-Survey-Report.pdf
11. Selvarajah S, Busch MP. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther 2012; 17:1423-1429.
12. Mortimer JY. Saving tests by pooling sera - how great are the benefits? J Clin Pathol 1980; 33:1120-1121.
13. Dawson GJ. The potential role of HCV core antigen testing in diagnosing HCV infection. Antivir Ther 2012; 17:1431-1435.
14. Gu S, Liu J, Zhang H, et al. Core antigen tests for hepatitis C virus: a meta-analysis. Mol Biol Rep 2012; 39:8197-8208.
15. Tian L, Wang RE, Chang Y-H. Molecular PINCERs® for biomarker analysis and their potential application in hepatitis C diagnosis. Antivir Ther 2012; 17:1437-1442.
16. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8:265-274.
17. Sagnelli E, Tonziello G, Pisaturo M, Sagnelli C, Coppola N. Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. Antivir Ther 2012; 17:1453-1458.
18. Dustin LB, Charles ED. Primary, post-primary and nonspecific immunoglobulin M responses in HCV infection. Antivir Ther 2012; 17:1449-1452.
19. Jehuda-Cohen T, Unal S. The challenges of hepatitis C diagnosis and the potential role of Stimmunology™ to address them. Antivir Ther 2012; 17:1415-1422.
20. Araujo AC. Antibody- and genome-based identification of recent HCV infection. Antivir Ther 2012; 17:1459-1464.
21. Blackard JT. HCV superinfection and reinfection. Antivir Ther 2012; 17:1443-1448.
22. Lara J, Khudyakov Y. Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance. Antivir Ther 2012; 17:1471-1475.
23. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20:23-38.
24. Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012; 13:313-323.
25. Khudyakov Y. Molecular surveillance of hepatitis C. Antivir Ther 2012; 17:1465-1470.
26. Ganova-Raeva LM, Dimitrova ZE, Campo DS, Khudyakov Y. Application of mass spectrometry to molecular surveillance of hepatitis B and C viral infections. Antivir Ther 2012; 17:1477-1482.